MRNA Flu Vaccine Shows Superior Protection in Global Trial

Industry Insights from Next Move Strategy Consulting

A large-scale Phase 3 trial has shown that a modified mRNA (modRNA) influenza vaccine provides significantly higher protection than a licensed, standard inactivated flu vaccine — setting the stage for a new era in seasonal influenza prevention. The findings, published in The New England Journal of Medicine, were reported through Medical Dialogues and reflect growing momentum toward modernized vaccine technology.

A Significant Shift from Traditional Flu Vaccines

Seasonal influenza vaccines have long relied on egg-based manufacturing, a legacy process that has persisted since the 1940s. While this method has enabled mass production, it requires strain selection months ahead of flu season, often resulting in mismatches between the vaccine and circulating influenza variants. Historical effectiveness has fluctuated widely, ranging from about 19% to 60%.

The new 

-vaccine adopts the mRNA technology that gained prominence during the COVID-19 pandemic. This approach enables more rapid updates and closer alignment with evolving influenza strains. According to the Medical Dialogues report, this technological shift could address long-standing limitations in flu vaccine performance.

Trial Overview and Core Findings

The study involved 18,476 healthy adults aged 18–64 across the United States, South Africa, and the Philippines during the 2022–2023 influenza season. Results showed that the modRNA vaccine achieved 34.5% greater efficacy than the comparator vaccine, meeting the criteria for both noninferiority and superiority. Most influenza-like illness cases were attributed to the A/H1N1 and A/H3N2 strains, with minimal influenza B activity during the study period.

Antibody responses for influenza A were similar across both vaccines. However, the modRNA vaccine did not meet noninferiority thresholds for influenza B strains, a finding that researchers noted will require further evaluation.

Safety observations found higher rates of local and systemic reactions among modRNA recipients. Injection-site reactions occurred in 70.1% of the modRNA group compared with 43.1% in the standard vaccine group. Systemic symptoms were reported in 65.8% of modRNA recipients versus 48.7% in the comparator group, with fever occurring in 5.6% and 1.7% respectively. Despite higher reactogenicity, overall safety profiles remained comparable, with only rare serious adverse events.

The study authors emphasized the importance of additional research in older adults, children, and individuals with chronic conditions, as these groups represent the populations most vulnerable to severe influenza complications.

A Turning Point in Influenza Immunization

Researchers noted that these outcomes represent a significant step forward in modernizing influenza vaccination. The ability to tailor vaccines more precisely to circulating strains could help create more consistent protection across flu seasons, particularly as the virus continues to evolve unpredictably.

Next Move Strategy Consulting’s View

From a market perspective, Next Move Strategy Consulting observes that these findings could accelerate a broader shift toward mRNA-based influenza vaccines. Higher efficacy in healthy adults may encourage greater investment in mRNA platforms, especially as public-health agencies seek strategies to reduce seasonal variability in vaccine performance.

As additional data emerge for older adults and high-risk groups, the Vaccine Market may begin transitioning from legacy egg-based production toward platforms capable of faster updates and more targeted strain matching. This shift may influence procurement decisions, R&D priorities, and long-term competitive dynamics within the global vaccine sector.

If future studies confirm similar or superior protection across diverse age groups, mRNA flu vaccines could become a central component of national immunization programs — signaling one of the most significant advancements in influenza prevention in decades.

Source: Medical Dialogues

Prepared by: Next Move Strategy Consulting